Aclaris Therapeutics Tops Q1 Revenue and EPS Forecasts
ACRS has more than doubled off its 52-week low of $1.16.
Summary
Aclaris Therapeutics reported first-quarter results, exceeding analyst expectations for both EPS and revenue. The company posted an EPS of -$0.15, beating the -$0.16 estimate, and revenue of $1.996 million, significantly above the $1.32 million forecast. While net income slightly missed estimates, the beats on key financial metrics are generally viewed positively. This financial update follows recent positive Phase 1A clinical trial results for its ATI-052 program, reinforcing a positive narrative for the company. Traders will likely view this as a supportive development, especially given the stock's proximity to its 52-week high.
At the time of this announcement, ACRS was trading at $4.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $667.6M. The 52-week trading range was $1.16 to $4.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.